Ecological momentary assessment (EMA) offers a holistic and naturalistic way to study how the events that unfold in daily life influence the relationship between psychological phenomenon in real time. Additionally, EMA methods allow researchers to collect data over a larger time span, which can provide crucial insights into how psychological symptoms interact over time. As such, the aim of the current study is to test how symptoms of generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD), major depressive disorder (MDD), Panic Disorder (PD), and Post-Traumatic Stress Disorder (PTSD) interact and influence one another longitudinally in clinical and non-clinical groups. Similarly, because GAD, SAD, MDD, PD, and PTSD are thought to be maintained by certain thinking styles that are repetitive and negative in nature, we will examine how such repetitive negative thinking (RNT) styles moderate the severity and interactions between psychological symptoms. More specifically, we will study how RNT maintains and predicts psychological symptoms of GAD, SAD, MDD, PD, and PTSD respectively within clinical and non-clinical groups. Moreover, we will examine how theoretical models of RNT, such as the contrast avoidance (CA) model can influence psychological symptoms transdiagnostically, such that CA may moderate the relationship between RNT styles and symptom interactions of multiple disorders at the same time. Therefore, the primary aim of the proposed study will be to investigate how the CA model of anxiety and depression can moderate RNT styles in clinical and non-clinical groups.

First, participants will be asked to complete a series of questionnaires to determine if they qualify for eligibility. Next, participants will be asked to complete a video-recorded diagnostic interview to confirm their study eligibility. This interview can be completed virtually or in-person (Moore building, UP campus). They will then complete additional baseline questionnaires. Participants will then be prompted to answer 3.5 minutes worth of questions 7 times a day for 7 days. Participants will be debriefed once the study is completed.

The purpose of this study is to find out if full-fat dairy and low-fat dairy have similar effects on risk factors for heart disease and diabetes. The study will take approximately 4 months to complete. During the study, participants will consume two types of dairy products: low-fat dairy (milk, yogurt, and cheese) and full-fat dairy (milk, yogurt, and cheese). Each type of dairy will be consumed for 6 weeks with a ≥4-week break between. Participants will be provided with all the dairy products. Testing will be conducted on two separate days at the beginning and end of each 6-week study period (a total of 8 testing days).

• The total time commitment for this study is approximately 4 months. It may take up to 7 months to complete the study from the time that you do the clinic screening visit. • During the study, you will be asked to consume two types of dairy products: low-fat dairy (milk, yogurt, and cheese) and full-fat dairy (milk, yogurt, and cheese). We will provide you with the dairy products. • Each type of dairy will be consumed for 6 weeks with a ≥4-week break between. • You will be asked to come to the Penn State Research Kitchen on campus every 7 days during each 6-week period to pick up your dairy products. • We will draw blood from you several times during the study, once at screening, and on two consecutive days at the start and end of each study period (total 9 times). • At the start and end of each period, we will also measure your blood pressure and perform non-invasive tests of artery health. • You will also be asked to collect a stool sample at the beginning and end of each study period (4 total).

$400

The potential participants must have Crohn's disease diagnosis. They should have had previous standard or advanced therapies for CD and have been intolerant or have lost response. They will be asked to sign and understand the informed consent. The volunteers will provide biological specimens blood, urine, stool, and the biopsy during endoscopy. They will answer daily diary questions about the symptoms, and complete questionnaires in the clinic. The screening will involve at least two visit and will last five weeks. They will be treated in the open label sub-study 1, or double-blinded randomization with placebo in the sub-study 2. The non-responders will be eligible for extended induction in sub-study 3. Each sub-study is 12 weeks long.

Participants will attend in person visit at the research clinical facility in Hershey, PA. If they sign the informed consent and want to participate, they will have vitals checked, and physical examination done. They will provide specimens such as blood and stool. They will answer questionnaires at home and in the clinic. The endoscopy will be done with biopsy to evaluate the disease response to the treatment at screening and week 12, or week 24 for the extended induction if applicable. The drug will be administered by subcutaneous injection in the clinic or at home. There will be a compensation for every completed clinic visit.

TBD

Exercise conducted above the shoulders (i.e., overhead exercise) can reduce blood flow and oxygen delivery to the exercising muscle due to the effects of gravity. This ultimately leads to greater muscle fatigue during overhead exercise tasks which can lead to fatigue-related injuries in occupational settings. Cold-water exposure increases blood pressure (i.e., cold pressor response) and could increase blood flow to exercising muscle by increasing muscular perfusion pressure (i.e., pressure that pushes blood into the muscle) during overhead exercise. This has the potential to reduce muscle fatigue during overhead exercise. However, no studies to date have investigated the effect of cold-water exposure on muscle fatigue during overhead exercise.

There will be 4 in person visits at Penn State Altoona for this study. The first visit will be ~1 hour and the other 3 visits will be ~30 minutes. Participants will complete questionnaires, undergo body composition measurements, and resting blood pressure and heart rate measurements during visit 1. Participants will complete a handgrip exercise test during each visit and their arm will be placed in different positions (overhead or straight in front) during the exercise test. Blood pressure, muscle oxygen levels, and blood flow will be measured during the exercise test. During two of the visits, the participant's foot will be exposed to cold water (~40 degrees F) with a cold-water foot sleeve for a brief period of time (1-3 minutes).

$25

This is a behavioral and biological research study that will examine how first-time parents’ interactions, brain activity, and hormone levels during pregnancy are related to later parenting and infant development. Participants will complete questionnaires, take part in video-recorded interaction tasks, wear a non-invasive brain activity monitor, and provide saliva samples. At a follow-up visit, parents and their infant will participate in similar activities together.

There will be two in-person lab visits for first-time expectant father–mother couples: one during pregnancy and one when the baby is about 8 months old. During both visits, participants will complete questionnaires, take part in interaction tasks, wear a soft headband to measure brain activity, and provide saliva samples. At the second visit, parents will complete similar activities together with their baby, including parent–infant interaction tasks.

Up to $375 per family (including travel reimbursement)

This trial will see if bevacizumab, in combination with carboplatin, paclitaxel, and pembrolizumab is better than carboplatin, paclitaxel, and pembrolizumab (the control arm) or carboplatin, paclitaxel, and bevacizumab in prolonging survival.

After it has been determined that it is safe for you to participate, you will be randomized to one of three treatment combinations. All of the arms will use real drug to treat your cancer. You will need to come to the clinic every three or every six weeks for treatment. You will continue treatment until your cancer comes back, you do not want treatment any more or the doctor feels it is not safe for you to continue. You will then be followed for five years once you complete all treatment.